Art of the Breakthrough
Scientists, clinicians, artists, patients, and patient advocates coming together to support breakthroughs in treatment and cures in Type 1 Diabetes.
Fundraising
We aim to raise funds through direct donations and through art sales across New England and Canada. We support companies and academic researchers engaging in cutting edge therapeutics by funding projects directly. Additionally with over 20 years experience designing comprehensive genomic profiling assays we can also work directly with drug developers to design bespoke, affordable NGS assays, with no IP restrictions. Such assays can be built to improve safety, enrich for responders, and overall accelerate getting advanced therapeutics to patients.
The latest in breakthroughs in T1D treatment
This exciting first in human study was one of the New England Journal of Medicine's top articles of 2025. It describes the remarkable results from a first clinical trial using Cas12b edited embryonic stem cells coaxed into islet cells. These cells were edited to remove antigens and injected into a man with long-standing type 1 diabete's forearm muscle. He did not receive any
immunosuppressive drugs and, at 12 weeks after transplantation, showed no immune response against the gene-edited cells. (Funded by the
Leona M. and Harry B. Helmsley Charitable Trust; EudraCT number, 2023-507988
-19-00; ClinicalTrials.gov number, NCT06239636.)
Teplizumab is a humanized monoclonal antibody to CD3 on T cells, and is approved by the FDA to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown.